A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-Acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder.

Trial Profile

A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-Acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Risperidone (Primary) ; Olanzapine
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 16 Feb 2010 Actual patient number changd from 585 to 586 added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual patient number changd from 585 to 586 added as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Actual patient number (585) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top